Sponsored Clinical Trials
Clinical trials study how well a new treatment or procedure works in people. The studies are done under careful supervision and help doctors identify the best treatments with the fewest side effects. Clinical trials help improve the standard of care for cancer and other diseases.
Breastcancer.org is featuring the clinical trials below to help raise awareness of new breast cancer treatments being studied, especially for metastatic disease. The content on this page is made possible by the support of our partners.
The safety and scientific validity of these studies are the responsibility of the studies’ sponsors and investigators. Listing a study here does not mean it has been evaluated by Breastcancer.org. The content on this page is made possible by the support of our partners.
Before you think about being part of a clinical trial, talk to your doctor and make sure you know the benefits and risks of participating in a trial. For more information on clinical trials, including how to find clinical trials, visit the Breastcancer.org Clinical Trials pages.
IPATunity130 Trial
The IPATunity130 trial is a phase III trial currently enrolling people with locally advanced or metastatic triple-negative breast cancer with a PIK3CA, AKT1, or PTEN genetic mutation. Triple-negative breast cancer is cancer that is estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative.
The trial is looking to see if adding the experimental medicine ipatasertib to Taxol (chemical name: paclitaxel), a taxane chemotherapy medicine, will offer more benefits than Taxol alone. Ipatasertib is an AKT inhibitor. The PI3K/AKT pathway helps all cells — both healthy and cancer cells — get the energy they need. When this pathway is mutated or overactivated, which can happen if the cancer has a PIK3CA, AKT1, or PTEN mutation, it can allow cancer cells to survive and grow. AKT inhibitors block a protein called AKT in this pathway with the goal of killing cancer cells.
Note: The IPATunity130 trial also has an arm that includes people diagnosed with hormone-receptor-positive breast cancer, but that arm is no longer enrolling participants.
CONTESSA Trial
The CONTESSA trial is a phase III trial for people diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer. The trial is looking to see if tesetaxel, an experimental taxane chemotherapy medicine that is taken orally as a pill, in combination with a low dose of Xeloda (chemical name: capecitabine) is better than Xeloda alone. Xeloda also is taken orally as a pill. This study is investigating the potential for a new all-oral regimen -- meaning a person would take only pills -- to treat advanced-stage disease.
To inquire about listing a clinical trial, please contact partnerships@breastcancer.org.
